EDITORIAL COMMENT

Nicotinamide and acute kidney injury

Miguel Fontecha-Barriuso¹,², Ana M. Lopez-Diaz¹, Sol Carriazo¹, Alberto Ortiz¹,²,³,⁴ and Ana Belen Sanz¹,²

¹Laboratory of Experimental Nephrology, Research Institute-Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, 28040 Madrid, Spain, ²REDINREN, Madrid, Spain, ³Department of Medicine, Universidad Autonoma de Madrid, 28049 Madrid, Spain and ⁴IRSIN, Madrid, Spain

Correspondence to: Alberto Ortiz; E-mail: aortiz@fjd.es

ABSTRACT

In a recent issue of ckj, Piedrafita et al. reported that urine tryptophan and kynurenine are reduced in cardiac bypass surgery patients that develop acute kidney injury (AKI), suggesting reduced activity of the kynurenine pathway of nicotinamide (NAM) adenine dinucleotide (NAD⁺) synthesis from tryptophan. However, NAM supplementation aiming at repleting NAD⁺ did not replete kidney NAD⁺ and did not improve glomerular filtration or reduce histological injury in ischaemic-reperfusion kidney injury in mice. The lack of improvement of kidney injury is partially at odds with prior reports that did not study kidney NAD⁺, glomerular filtration or histology in NAM-treated wild-type mice with AKI. We now present an overview of research on therapy with vitamin B3 vitamers and derivate molecules (niacin, Nicotinamide [NAM; niacinamide], NAM riboside [Nicotinamide riboside (NR)], Reduced nicotinamide riboside [NRH] and NAM mononucleotide) in kidney injury, including an overview of ongoing clinical trials, and discuss the potential explanations for diverging reports on the impact of these therapeutic approaches on pre-clinical acute and chronic kidney disease.

Keywords: acute kidney injury, chronic kidney disease, NAD, nicotinamide, treatment, vitamin B3

VITAMIN B3 AND NAD⁺

Vitamin B3 is a water-soluble vitamin family that includes three vitamers, nicotinic acid (niacin), nicotinamide (NAM; niacinamide) and NAM riboside (NR). The three are precursors of NAM adenine dinucleotide (NAD⁺) and NAD phosphate (NADP⁺), which may be synthesized de novo from dietary vitamin B3 vitamers and derivate molecules (niacin, Nicotinamide [NAM; niacinamide], NAM riboside [Nicotinamide riboside (NR)], Reduced nicotinamide riboside [NRH] and NAM mononucleotide) in kidney injury, including an overview of ongoing clinical trials, and discuss the potential explanations for diverging reports on the impact of these therapeutic approaches on pre-clinical acute and chronic kidney disease.

Keywords: acute kidney injury, chronic kidney disease, NAD, nicotinamide, treatment, vitamin B3

Received: 8.8.2021; Editorial decision: 9.8.2021
© The Author(s) 2021. Published by Oxford University Press on behalf of ERA.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
FIGURE 1: NAD⁺ metabolic pathways. NAD⁺ production from NAM or from NR consists of two steps, while production from niacin includes three enzymatic reactions and is known as the Preiss–Handler pathway. In contrast, NAD⁺ synthesis from tryptophan through the kynurenine pathway requires six enzymatic steps to yield quinolinic acid, which is then transformed to NAMN that, in turn, is the precursor of NAD⁺ in the Preiss–Handler pathway. NAD⁺ levels can be decreased by enzyme such as CD38, CD157 and SARM1 (sterile alpha and Toll/interleukin-1 receptor motif-containing 1). CD38 also degrades NR and NMN [3]. Tryptophan may also be a source of uremic toxins, which are either metabolites of the kynurenine pathway or of indole, which is generated by bacterial tryptophanase in the gut.
Nicotinamide and AKI  | 2455

from the kynurenine pathway (kynurenine, kynurenic acid, anthranilic acid, 3-hydroxykynurenine, 3-hydroxyanthranilic acid and quinolinic acid), the circulating levels of which are increased while those of tryptophan are decreased in persons with chronic kidney disease (CKD), or toxins derived from the gut microbiota metabolism of tryptophan to indole [e.g. indoxyl sulphate (IS), indole acetic acid (IAA) and indoxyl-β-n-glucuronide (IDG)] [6, 7] (Figure 1).

NAD⁺ has three key functions: it is an essential coenzyme in electron-transfer reactions, a substrate for NAD⁺-consuming enzymes and an endogenous agonist of P2Y1 and P2Y11 cell surface purinergic receptors.

The role of NAD⁺ in electron-transfer reactions is essential, because >400 enzymes require NAD⁺ and NADPH, mainly to accept or donate electrons for redox reactions. NAD⁺ is involved mainly in energy-producing reactions in the mitochondria, meaning catabolism, while NAD⁺-consuming enzymes of both synthetic reactions, meaning anabolism. NAD⁺ is also crucial for the regeneration of components of detoxification and antioxidant systems. To accomplish these functions, cellular NAD⁺ is kept in the oxidized state (NAD⁺), whereas cellular NAD⁺ is maintained in a reduced state (NADPH) [2, 8].

NAD⁺-consuming enzymes include ADP-ribosyltransferases (ARTs), poly (ADP-ribose) polymerases (PARPs), sirtuins and NAD glycohydrolases/ADP-ribosylcyclases like CD38 and CD157. ARTs and PARPs catalyse ADP-ribosyl transfer reactions [9], while sirtuins catalyse the removal of acetyl groups from acetylated proteins, using ADP-ribose from NAD⁺ as an acceptor for acetyl groups. They play a key role in histone post-translational modifications [10].

NAD⁺ binding to P2Y1 receptors functions as an inhibitory neurotransmitter at neuromuscular junctions in visceral smooth muscles [11], while binding to P2Y11 receptors in neutrophils activates a signalling cascade involving cyclic ADP-ribose and increased intracellular calcium, stimulating superoxide generation and chemotaxis [12].

CLINICAL USE OF VITAMIN B3

Vitamin B3 vitamins niacin and NAM may be prescribed to treat pellagra. Clinical trials of higher dose vitamin B3 for other indications date back to the 20th century. In 1998, Guyton stated that ‘the use of niacin to prevent or treat atherosclerotic cardiovascular disease is based on strong and consistent evidence from clinical trials’ [13]. The ClinicalTrials.gov web page lists 140 completed clinical trials testing niacin, NAM or NR (Figure 3A). Despite this, current clinical indications are limited. Niacin has been used to treat dyslipidaemia, especially hypertriglyceridaemia with low high-density lipoprotein cholesterol levels, but NAM does not have the lipid-lowering effect [14]. Niacin also lowers lipoprotein(a) (Lp(a)) levels by around 25%, but there is no evidence that this reduces clinical events. However, niacin is no longer recommended for dyslipidaemia, except in specific clinical situations (e.g. severe hypertriglyceridaemia resistant or intolerant to other therapeutic approaches) [15]. Niacin extended-release still lists an indication to reduce the risk of recurrent non-fatal myocardial infarction in patients with a history of myocardial infarction and hyperlipidaemia [16]. Oral NAM was also safe and effective in reducing the rates of new non-melanoma skin cancers and actinic keratoses in high-risk patients [17]. However, pharmacological doses of niacin or NAM are poorly tolerated. The dose-limiting adverse effect of niacin is skin flushing, caused by an increase in the vasodilator prostacyclin. Additional adverse effects of niacin and NAM include pruritus, skin rash, gastrointestinal disturbances and thrombocytopenia [18, 19]. Liver cell damage has been observed at intakes of niacin as little as 750 mg/day [20]. In addition, high niacin doses impair glucose tolerance, presumably by

---

**FIGURE 2:** Dietary sources of vitamin B3 vitamers and pharmacological dosing of niacin. Pharmacological doses of niacin are over 100-fold higher that the US recommended dietary allowance. The size of each square is proportional to the magnitude of the dose.

---

**TABLE 1:** Adverse effects of niacin and NAM.

| Adverse Effects                                                                 | Niacin                                                                 | NAM           |
|---------------------------------------------------------------------------------|------------------------------------------------------------------------|---------------|
| • Flushing (80%)                                                                | Best tolerated than niacin                                             |               |
| • Pruritus, paresthesias, nausea (20%)                                           | Better tolerated than niacin                                           |               |
| • Other: statin-induced myopathy, hepatotoxicity, hyperglycaemia, hyperuricemia and gout, increased plasma homocysteine, increased risk of infection and perhaps bleeding |  |               |
| • Other: statin-induced myopathy, hepatotoxicity, hyperglycaemia, hyperuricemia and gout, increased plasma homocysteine, increased risk of infection and perhaps bleeding |  |               |
| • Other: statin-induced myopathy, hepatotoxicity, hyperglycaemia, hyperuricemia and gout, increased plasma homocysteine, increased risk of infection and perhaps bleeding |  |               |

---

**CLINICAL USE OF VITAMIN B3**

Vitamin B3 vitamins niacin and NAM may be prescribed to treat pellagra. Clinical trials of higher dose vitamin B3 for other indications date back to the 20th century. In 1998, Guyton stated that ‘the use of niacin to prevent or treat atherosclerotic cardiovascular disease is based on strong and consistent evidence from clinical trials’ [13]. The ClinicalTrials.gov web page lists 140 completed clinical trials testing niacin, NAM or NR (Figure 3A). Despite this, current clinical indications are limited. Niacin has been used to treat dyslipidaemia, especially hypertriglyceridaemia with low high-density lipoprotein cholesterol levels, but NAM does not have the lipid-lowering effect [14]. Niacin also lowers lipoprotein(a) (Lp(a)) levels by around 25%, but there is no evidence that this reduces clinical events. However, niacin is no longer recommended for dyslipidaemia, except in specific clinical situations (e.g. severe hypertriglyceridaemia resistant or intolerant to other therapeutic approaches) [15]. Niacin extended-release still lists an indication to reduce the risk of recurrent non-fatal myocardial infarction in patients with a history of myocardial infarction and hyperlipidaemia [16]. Oral NAM was also safe and effective in reducing the rates of new non-melanoma skin cancers and actinic keratoses in high-risk patients [17]. However, pharmacological doses of niacin or NAM are poorly tolerated. The dose-limiting adverse effect of niacin is skin flushing, caused by an increase in the vasodilator prostacyclin. Additional adverse effects of niacin and NAM include pruritus, skin rash, gastrointestinal disturbances and thrombocytopenia [18, 19]. Liver cell damage has been observed at intakes of niacin as little as 750 mg/day [20]. In addition, high niacin doses impair glucose tolerance, presumably by
increasing insulin sensitivity, and long-term niacin therapy was associated with a modest increase in risk of new onset Type 2 diabetes mellitus [21]. NAM is generally better tolerated than niacin, although gastrointestinal disturbances and signs of liver toxicity have been reported at doses >10 g/day [22].

NR was beneficial in pre-clinical and early clinical studies on diabetes, neurodegenerative disorders and cardiovascular diseases without the serious adverse effects observed with similar doses of niacin or NAM [23, 24]. In healthy volunteers, peak doses of up to 1000 mg twice daily were tolerated in a short-term (up to 9 days) open-label trial, and resulted in doubling of circulating NAD$^+$ levels [25]. Single doses of 100, 300 and 1000 mg of NR led to dose-dependent increases in the blood NAD$^+$ metabolome [23]. The rise in peripheral blood mononuclear cells (PBMCs) niacin adenine dinucleotide was a sensitive biomarker of effective NAD$^+$ depletion, despite not being in the NR to NAD$^+$ pathway (Figure 1).

**VITAMIN B3 IN CKD**

Vitamin B3 vitamers have been tested in clinical trials for the treatment of hyperphosphataemia in CKD (Figure 3B and Table 1). In CKD, niacin [26] or NAM [18, 19, 30], either alone or in combination with other phosphate binders, reduced serum phosphate levels in most trials through inhibition of the expression of the intestinal phosphate transporter NaPi2b by poorly characterized mechanisms. The main metabolite of NAM, N-methyl-2-pyridone-5-carboxamide, may accumulate in haemodialysis patients [19]. Overall, tolerance was suboptimal and regulatory authorities did not approve this indication. Additional studies unsuccessfully explored the impact of niacin on flow-mediated dilation and of NAM in sirtuin deacetylase activity [27, 28] (Table 1). An ongoing trial is testing NR to improve aerobic capacity in persons with CKD, while four other trials are testing NAM (1–3 g/day) or NR (1 g/day) for acute kidney injury (AKI), as discussed below (Figure 3C and Table 1).

**VITAMIN B3 AS A KIDNEY PROTECTIVE STRATEGY IN EXPERIMENTAL CKD**

Administration of vitamin B3 vitamers NAM or NR, as well as downstream metabolites such as NAM mononucleotide (NMN), has been tested in experimental CKD with the aim of preserving kidney function.

NAM supplementation [200, 400, 800 mg/kg, intraperitoneal (i.p.) 1 h before unilateral ureteral obstruction (UUO) and daily until Day 13] reduced renal interstitial fibrosis, tubular injury and inflammation at Day 14 in mice [31]. NAM (250 mg/kg i.p. 3 days before UUO and continuing to Day 7) also reduced fibrosis and Neutrophil gelatinase-associated lipocalin (NGAL) levels in mice at Day 7 [32]. Moreover, in murine aristolochic acid nephropathy NAM (500 mg/kg, i.p. 1 day before and continuously up to Day 14) reduced tubular injury and cytokine expression on Day 15, but this effect was weaker than in the UUO model [32]. Drinking NAM (0.3, 0.6 or 1.2% NAM) from Day 0 until the end of study (6 weeks) improved kidney function and decreased tubular injury and inflammation in murine adriamycin-induced CKD. However, in advanced stages of adenine-CKD, drinking 0.3 or 0.6% NAM from Week 6 of adenine diet until sacrifice at 10 weeks did not improve kidney fibrosis and function [33].

Dietary NR supplementation (800 mg/kg/day) 1 week prior to CKD induction until sacrifice did not prevent CKD progression, assessed as kidney function [glomerular filtration rate (GFR)], blood urea nitrogen (BUN) and serum creatinine (sCr)] and fibrosis, in two murine models of CKD induced by UUO or proteinuria, despite increased kidney NAD$^+$ levels [34].

N Mn administration (500 mg/kg, i.p.) 20 min prior to unilateral ischaemia–reperfusion injury (IRI) and daily for 3 days after IRI prevented tubular damage and cell death at Day 3 and attenuated tubular senescence and fibrosis at Day 21 [35]. Additionally, N Mn in the recovery phase (500 mg/kg i.p. on Days 3 and 14 after surgery) reduced DNA damage, inflammation and fibrosis at Day 21 after IRI [35].

Overall, published experience supports a preventive but not therapeutic role of NAM or NMN in pre-clinical CKD. However, the lack of benefit observed for NR, despite increasing kidney NAD$^+$ levels, casts doubt on the mechanisms of protection and raises the spectrum of publication bias.

**VITAMIN B3 IN AKI**

Vitamin B3 vitamers are up taken by proximal tubule brush borders through the sodium monocarboxylate transporter for niacin and through unidentified transporters for NAM [36, 37]. Additionally, kidneys may also synthetize NAD$^+$ from
tryptophan, as do hepatocytes [38]. During AKI, mitochondrial respiration and function are impaired [39], leading to a substantial decrease in NAD\(^+\) levels, which may compromise energy production and ultimately the core kidney function of selective solute transport [1, 40]. Peroxisome proliferator-activated receptor gamma co-activator 1 alpha (PGC-1\(\alpha\)) is a master regulator of mitochondrial biogenesis. Upon deacetylation by Sirtuin 1, PGC-1\(\alpha\) translocates to the nucleus where it is a transcriptional coactivator of genes encoding mitochondrial proteins [39]. Indeed, kidney tubule PGC-1\(\alpha\) coordinates NAD\(^+\) de novo biosynthesis [40], constituting a positive feedback loop where PGC-1\(\alpha\) and NAD\(^+\) upregulate each other, and both are downregulated in AKI [40–42]. Therefore, decreased NAD\(^+\) levels may lead to reduced PGC-1\(\alpha\) activity and mitochondrial biogenesis and vice versa. During AKI, PGC-1\(\alpha\) is downregulated, and PGC-1\(\alpha\) deficiency promotes local inflammation and increases the sensitivity to AKI [39, 42, 43]. The expression of quinolinate phosphoribosyltransferase (QPRT), which catalyses the final step of the tryptophan pathway, is also reduced in AKI, leading to increased quinolate levels and decreased NAD levels [27]. Indeed, as is the case for PGC-1\(\alpha\)-deficient mice, QPRT\(^+\)/C0 mice have increased susceptibility to IRI AKI [27]. The increased sensitivity of these genetically modified mice to AKI may be improved by vitamin B3 vitamers, as discussed below.

Based in part on these observations, AKI has been proposed to represent a state of NAD\(^+\) impairment that can be therapeutically targeted by approaches that replete NAD\(^+\) [44]. Therapeutic approaches aimed at increasing kidney NAD\(^+\) levels in AKI include administration of NAM, NR, NRH or NMN (Figure 4) (Table 2).
Table 1. Clinical trials of vitamin B3 vitamers in kidney disease: niacin, NAM or NR

| Trial                  | Population                                                                 | n   | Phase | Comparator                             | Primary endpoint                                                                 | Key secondary endpoint                                                                 | Status/results                | Completion | Comments |
|------------------------|-----------------------------------------------------------------------------|-----|-------|----------------------------------------|---------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-------------------------------|------------|----------|
| Ongoing trials         |                                                                             |     |       |                                        |                                                                                 |                                                                                         |                               |            |          |
| CoNR                   | Non-KRT CKD (eGFR <50)                                                      | 30  | 2     | Coenzyme Q10/NR/placebo               | Aerobic capacity                                                                | Inflammation                                                                          | Recruiting                   | 2021       | –        |
| CoNR                   | Elective open aortic arch replacement or repair                             | 238 | 2     | NR 1 g/day + pterostilbene (Basis\(\text{TM}\))/placebo | AKI incidence (eGFR)                                                           |                                                                                        | Recruiting                   | 2024       | –        |
| NIRVANA (NCT04818216)  | COVID-19 with persistent AKI                                               | 100 | 2     | NR 1 g/day/placebo                    | Whole blood NAD\(^+\), kidney function, proteinuria                           |                                                                                        | Recruiting                   | 2023       | –        |
| VITAKI (NCT04589546)   | Septic shock                                                               | 310 | 3     | NAM 1 g/day/placebo                   |                                                                                   |                                                                                        | Not yet recruiting           | 2024       | –        |
| NACAM (NCT04750616)    | Cardiac surgery-associated myocardial injury                                | 304 | 2     | NAM 3 g/day pre-surgery and post-surgery Days 1 and 2 a/placebo | Troponin T                                                                      | eGFR                                                                     | Not yet recruiting           | 2024       | –        |
| Completed trials\(^b\) |                                                                             |     |       |                                        |                                                                                 |                                                                                         |                               |            |          |
| AIM-HIGH (NCT00120289) | eGFR<60, >45 years old, established vascular disease and atherogenic dyslipidaemia, sCr<2.5 mg/L | 352 of 3414 | 3     | Niacin 1.5 or 2 g + simvastatin/niacin 50 mg + placebo + simvastatin | Flow-mediated dilation by brachial artery reactivity Composite CVD endpoint\(^c\) | Other CVD endpoints Serum phosphate CKD-MBD parameters | Terminated/lack of efficacy for primary endpoint. Post hoc analysis: lower serum phosphate at 3 years, no change in other CKD-MBD parameters Increased circulating NAD\(^+\) metabolites, well tolerated, associated with less AKI | 2011       | –        |
| NCT02701127 [27]       | Cardiac surgery at risk of AKI                                             | 55  | 1     | NAM 1 or 3 g/placebo                  | Serum NAM metabolites                                                           | Urine NAM metabolites                                                             | Increased circulating NAD\(^+\) metabolites, well tolerated, associated with less AKI | 2017       | –        |
| NIAC-PKDI (NCT02140814) [28] | Polycystic kidney disease                                                 | 10  | 2     | NAM/uncontrolled                      | Sirtuin deacetylase activity (12 months)                                       | Sirtuin deacetylase activity (6 months)                                           | No sustained inhibition of sirtuin activity                                      | 2016       | –        |
| NIAC-PKDI (NCT02558595) [28] | ADPKD, eGFR >50                                                           | 36  | Pilot | NAM/placebo                           | Acetylated\(total\) p53 ratio in PBMC                                           | TKV, eGFR, urinary MCP-1                                                            | No differences in outcomes                                                | 2017       | –        |
| COMBINE/ NCT02258074   | CKD                                                                         | 205 | 2     | NAM/lanthanum/placebo                 | Serum phosphate, FGF23                                                           | Markers of CKD-MBD, CVD, CKD progression CKD-MBD parameters CKD-MBD parameters lipids | No differences in outcomes                                                | 2019       | Up to 42% stopped study drug |
| NCT00508885 [29]       | Peritoneal dialysis                                                        | 17  | 1, 2  | NAM/placebo plus phosphate binder     | Plasma phosphate                                                                | CKD-MBD parameters                                                             | Lower plasma phosphate                                                | 2007       | –        |
| 2013-000488-95 [19]    | Haemodialysis patients                                                     | 738 | 3     | NAM/placebo plus phosphate binder     | Serum phosphate                                                                | CKD-MBD parameters CKD-MBD parameters lipids                                      | Lower serum phosphate                                                | 2017       | –        |

(continued)
Intraperitoneal NAM improved kidney function as assessed by sCr in mice with bilateral IRI or cisplatin-induced AKI [27, 40] (Table 2). However, in one IRI AKI study, the therapeutic effect was only noted in PGC-1α knock-out (KO) mice, which have impaired mitochondrial function and lower spontaneous kidney NAM levels. Tran et al. explored two dosing schemes in IRI. Administration of four daily doses (400 mg/kg NAM, i.p.) before IRI protected PGC-1α KO mice, as assessed by sCr levels at 24 h (sCr ~1.6 versus ~0.6 mg/dL, P < 0.01), but not wild-type (WT) mice (sCr ~0.75 versus ~0.50 mg/dL, P = not significant) [40]. Control WT AKI mice had less severe AKI at this time-point than PGC-1α KO mice. A single dose of 400 mg/kg NAM administered i.p. 18 h after IRI protected WT mice as assessed by sCr levels at 24–72 h [40] (Figure 4). In cisplatin nephrotoxicity, two doses of 400 mg/kg NAM, administered i.p. 1 day before and at the time of cisplatin injection, reduced sCr levels at 72 h [40]. Poyan Mehr et al. administrated three doses of 400 mg/kg NAM i.p. 24 and 1 h prior to IRI and 4–6 h after IRI, and observed milder AKI in both WT (sCr ~1.9 versus ~1.1 mg/dL at 24 h, P < 0.05) and QPRT-deficient mice (sCr ~2.6 versus ~1.5 mg/dL at 24 h, P < 0.01), noting that AKI was more severe in control QPRT-deficient AKI mice than in control WT mice with AKI (P < 0.05) [27].

NR administered 10 days before AKI induction until sacrifice (400 mg/kg/day in diet) improved kidney function and decreased tubular injury at 48 h in IRI-induced AKI and at 72 h in cisplatin AKI [34]. In contrast, NR administration by oral gavage (500 mg/kg/day) for 2 weeks before IRI surgery and up to 24 h later did not protect rats at 24 h or 14 days after IRI, as assessed by sCr or kidney NGAL mRNA, despite repleting tissue NAD⁺ [48].

A reduced form of NR, NRH, administered i.p. (250 mg/kg) at the time that cisplatin and at 24, 48 and 72 h thereafter, significantly reduced BUN levels, tubular injury and recovered kidney NAD⁺ levels at 72 h in mice [46]. NMNH is a reduced form of NMN that protects cultured kidney cells from hypoxia and in vivo increased NAD⁺ levels in blood and several organs including the kidneys [49].

NMN administration (500 mg/kg i.p.) immediately after cisplatin injection and for three consecutive days until sacrifice significantly protected 3- and 20-month-old mice from cisplatin-induced AKI at 72 h as assessed by sCr, BUN, tubular damage and tubular cell death [45]. In the same report, NMN 500 mg/kg i.p. right before IRI and 24 h after reperfusion, significantly protected 3-month-old mice as assessed at 48 h by sCr, BUN and tubular damage [45].

Overall, as it was the case for CKD, published experience supports a preventive and even therapeutic role of NAM, NR, NRH or NMN in pre-clinical AKI. However, as for CKD, there were mixed results reported for NR, with one study failing to observe benefit in rat IRI AKI despite increasing kidney NAD⁺ levels.

Regarding clinical translation, urine quinolinate levels were higher in cardiac surgery patients that develop AKI [27]. A Phase I pilot study addressed the safety and impact on NAM levels of administering NAM to prevent AKI in cardiac surgery [27]. Three daily doses of either 1 (n = 13) or 3 g (n = 14) oral NAM or placebo (n = 14) were administered on the day prior to on-pump cardiac surgery, on the day of surgery and on the first post-operative day. Circulating and urinary NAM, NMN and N1-methyl-NAM (MNA, a metabolite not in the NAD⁺ pathway) increased without major safety concerns. Patients on the higher dose had persistently elevated serum NAM and NMN and urine NAM at 48 h. In a post hoc analysis, treatment with NAM resulted in lower frequency of AKI events in both AKI groups combined: 4/27 (15%)
Table 2. Therapeutic approaches aimed at increasing NAD⁺ availability in preclinical AKI

| Model | Drug | Dosing schedule | Mice | Time of readout | Result | Comments | Ref |
|-------|------|-----------------|------|-----------------|--------|----------|-----|
| Cisplatin | NAM | 400 mg/kg i.p. 1 day before and at time of cisplatin | PGC-1α+/− | 24, 48 and 72 h | sCr at 72 h; Kidney NAM at 24 h; Tubular damage; Cell death; Mitochondrial density | Protection | [40] |
| NMN | 500 mg/kg i.p. immediately after cisplatin injection and at 24, 48 and 72 h | 3- and 20-month-old WT | 72 h | sCr, BUN; Kidney NAM at 24 h; Tubular damage | Protection in 3- and 20-month old | [45] |
| NR | 400 mg/kg/day, in diet 10 days prior to cisplatin and up to sacrifice | WT | 72 h | sCr, BUN; Tubular damage | Protection | [34] |
| NRH | 250 mg/kg i.p. at time of cisplatin and at 24, 48 and 72 h | WT | 72 h | BUN; Tubular damage; Kidney NAD | Protection | [46] |
| IRI | NAM | 400 mg/kg i.p. 4 daily doses before IRI | WT, PGC-1α−/− | 24 h | sCr; Kidney NAM in PGC-1α−/− mice | No protection in WT mice | [40] |
| | | 400 mg/kg i.p. 18 h after IRI | PGC-1α−/−, WT, QPRT+/− | 24, 48 and 72 h | sCr at all points; sCr | Protection | [40] |
| | | 400 mg/kg i.p. 24 and 1 h pre-IRI and 4-6 h after IRI | WT | 24 h | sCr | Protection | [27] |
| | NMN | 400 mg/kg i.p. 18 h after IRI | WT | BUN 48 h; GFR −24 h, +24 h | BUN and measured GFR do not change | No protection | [47] |
| | | 500 mg/kg i.p. right before IRI and 24 h after reperfusion | WT | 48 h | sCr, BUN; Tubular damage | Protection | [45] |
| NR | 400 mg/kg/day, in diet 10 days before IRI and up to sacrifice | WT | 48 h | sCr, BUN; Tubular damage | Protection | [34] |

NRH, 1-[2R, 3R, 4S, 5R]-3,4-Dihydroxy-5-(hydroxymethyl)[tetrahydrofuran-2-yl]-4H-pyridine-3-carboxamide, which is the NAD⁺ precursor in mammalian cells. BUN, blood urea nitrogen.

Not specified.

versus 7/14 (50%) in the placebo group (p < 0.05) [27]. However, it has been pointed out that sCr started to decrease in NAM-treated patients on day 0 and reached a nadir on Day 1, raising the spectrum of interference with sCr method and/or creatinine kinetics [47]. Four ongoing placebo-controlled clinical trials exploring NAM or NR to prevent or treat AKI are expected to be completed between 2023 and 2024 (Table 1). Of these, one Phase 2 (NR in aortic arch surgery) and one Phase 3 clinical trial (NAM in septic shock) have kidney function as primary outcome.

**DIVERGENT EFFECTS OF NAM SUPPLEMENTATION ON MURINE IRI AKI**

In a recent issue of CKJ, Piedrafita et al. [47] reported that urine tryptophan and kynurenine were reduced in cardiac bypass surgery patients who developed AKI, especially in those with more severe AKI. However, receiver operating characteristic (ROC) curves with both markers showed a poor discrimination for AKI severity or post-operative mortality. Based on the low levels of urine tryptophan and kynurenine, they hypothesized that reduced activity of the kynurenine pathway may contribute to AKI and explored the effect of NAM supplementation on murine IRI AKI. However, NAM did not improve kidney function as assessed by measured GFR at 36 h or BUN at 48 h in male or female mice, nor did it reduce histological injury or kidney Ki6-1 expression, the latter being even higher in NAM-treated males. These findings are in contrast with the protection provided by NAM in murine IRI AKI in studies by Poyan Mehr et al., but may be aligned with results by Tran et al. [27, 40]. What may explain the different results obtained?

The dosing schedule was similar for Piedrafita and Poyan Mehr. Surgical methods were also similar, but ischaemia time differed: 20 min for Tran and Poyan Mehr [27, 40] and 25 min for Piedrafita [47]. One possibility is that the longer ischaemia time decreased the efficacy of the intervention, but this hypothesis should be assessed experimentally. Furthermore, Tran and Poyan Mehr assessed sCr, while Piedrafita assessed BUN and measured GFR by sinistrin-FITC clearance. Therefore, further studies, using the same readouts of kidney injury, are necessary to clarify the effect of NAM over AKI. In this regard, an impact of NAM on creatinine generation, kinetics or assessment cannot be excluded, and Tran and Poyan Mehr did not report on further evidence of kidney injury such as kidney gene expression or histological injury.

Of interest, only Piedrafita et al. assessed the impact of NAM supplementation on kidney NAD⁺ levels, and failed to observe improvement over AKI controls at the studied timepoint. This may explain the failure to observe kidney protection, but it would be necessary to compare these data with the impact of NAM over kidney NAD⁺ levels in studies in which NAM was protective.

Finally, the origin of mice differed: Janvier supplied C57BL/6JRj mice to Piedrafita, and Jackson supplied C57BL6J for Tran and Poyan Mehr. A different origin for the mice may have impacted their gut microbiota on top of any potential strain
differences. The gut microbiota is a key modulator of dietary tryptophan metabolism, including the pathway leading to niacin [50].

GAPS IN KNOWLEDGE THAT NEED TO BE FILLED

In conclusion, administering vitamin B3 vitamers and other metabolites in the NAD⁺ biosynthesis pathway is a hot topic in kidney protection. In addition to mostly positive pre-clinical data in models of both AKI and CKD, several randomized clinical trials are ongoing in AKI and at least two have a primary endpoint of kidney function. The clinical development stage generates a sense of urgency in the need to fully understand which are the optimal molecules, dose, timing and route of administration that protect the kidneys, as well as to understand the molecular mechanisms of protection. However, several studies could not reproduce the protection described by other authors in AKI or CKD, in some cases despite documentation of repletion of kidney NAD⁺. This raises questions that so far remain answered. The recent concept of pre-clinical multicentre randomized controlled trials may help address some of the pending issues regarding the impact of NAM or other vitamin B3 vitamers or NAD⁺ precursors on pre-clinical kidney injury [51]. Knowledge derived from such studies, which incorporate the different levels of heterogeneity that are expected in clinical care, may better guide the design of clinical trials.

FUNDING

This study was supported by FIS/Fondos FEDER [PI19/00588, P19/00815, DTS18/00032, ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071) and ISCIII-RETIC REDinREN (RD016/0009)], Sociedad Española de Nefrología, FRIAT, Comunidad de Madrid en Biomedicina B2017/BMD-3686 CIFRA2-CM.

CONFLICT OF INTEREST STATEMENT

A.O. is Editor-in-Chief of ckj, and has received consultancy or speaker fees or travel support from Astellas, AstraZeneca, Amicus, Amgen, Fresenius Medical Care, Bayer, Sanofi-Genzyme, Menarini, Kyowa Kirin, Alexion, Otsuka and Vifor Fresenius Medical Care Renal Pharma, and is Director of the Catedra Mundipharma-UAM of diabetic kidney disease and the Catedra AstraZeneca-UAM of CKD and electrolytes. The results presented in this paper have not been published previously in whole or part.

REFERENCES

1. Ralito KM, Rhee EP, Parikh SM. NAD. Nat Rev Nephrol 2020; 16: 99–111
2. Nikiforov A, Kulikova V, Ziegler M. The human NAD metabolism: Functions, metabolism and compartmentalization. Crit Rev Biochem Mol Biol 2015; 50: 284–297
3. Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. 1998. https://www.ncbi.nlm.nih.gov/books/NBK114310/ (5 April 2018, date last accessed)
4. Pazirandeh S, Burns DL. Overview of Water-soluble Vitamins. https://www.uptodate.com/contents/overview-of-water-soluble-vitamins (10 July 2021, date last accessed)
5. Castillo-Rodríguez E, Fernandez-Prado R, Esteras R et al. Impact of altered intestinal microbiota on chronic kidney disease progression. Toxins (Basel) 2018; 10: 300
6. Fernandez-Prado R, Esteras R, Perez-Gomez MV et al. Nutrients turned into toxins: microbiota modulation of nutrient properties in chronic kidney disease. Nutrients 2017; 9: 489
7. Sallée M, Dou L, Cerini C et al. The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease. Toxins (Basel) 2014; 6: 934–949
8. Agledal I, Niere M, Ziegler M. The phosphate makes a difference: cellular functions of NADP. Redox Rep 2010; 15: 2–10
9. Liu C, Yu X. ADP-ribosyltransferases and poly ADP-ribosylation. Curr Protein Pept Sci 2015; 16: 491–501
10. Hwang ES, Song SB. Nicotinamide is an inhibitor of SIRT1 in vitro, but can be a stimulator in cells. Cell Mol Life Sci 2017; 74: 3347–3362
11. Mutafova-Yambolieva VN, Hwang SJ, Hao X et al. Beta-nicotinamide adenine dinucleotide is an inhibitory neurotransmitter in visceral smooth muscle. Proc Natl Acad Sci USA 2007; 104: 16359–16364
12. Moresci I, Bruzzzone S, Nicholas RA et al. Extracellular NAD⁺ is an agonist of the human P2Y11 purinergic receptor in human granulocytes. J Biol Chem 2006; 281: 31419–31429
13. Guyton JR. Effect of niacin on atherosclerotic cardiovascular disease. Am J Cardiol 1996; 82: 18U–29U
14. Peechakara BV, Gupta M. Vitamin B3. In: StatPearl. Treasure Island (FL): StatPearls Publishing; 2021
15. https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information?search=niacin&source=drug_gene&drug_name=niacin&drug_search=1&selectedTitle=1–125&usage_type=panel&kp_tab=drug_grammar&display_rank=1 (10 July 2021, date last accessed)
16. NIASPAN (Niacin Extended-release) Highlights of Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020381Orig1s051lbl.pdf (10 July 2021, date last accessed)
17. Chen AC, Martin AJ, Choy B et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 2015; 373: 1618–1626
18. Kettel M, Wieczek A, Rosenkranz AR et al. Efficacy and safety of a novel nicotinamide modified-release formulation in the treatment of refractory hyperphosphatemia in patients receiving hemodialysis—A randomized clinical trial. Kidney Int Rep 2021; 6: 594–604
19. Lenglet A, Liabeuf S, El Esper N et al. Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrol Dial Transplant 2017; 32: 870–879
20. MacKay D, Hathcock J, Guarneri E. Niacin: chemical forms, bioavailability, and health effects. Nutr Rev 2012; 70: 357–366
21. Sazonov V, Maccubbin D, Sisk CM et al. Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose. Int J Clin Pract 2013; 67: 297–302
22. Rolfe HM. A review of nicotinamide: treatment of skin diseases and potential side effects. J Cosmet Dermatol 2014; 13: 324–328
23. Trammell SA, Schmidt MS, Weidemann BJ et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun 2016; 7: 12948
24. Mehmel M, Jovanovic N, Spitz U. Nicotinamide riboside—the current state of research and therapeutic uses. Nutrients 2020; 12: 1616
A 26. Malhotra R, Katz R, Hoofnagle A et al. The effect of extended release niacin on markers of mineral metabolism in CKD. Clin J Am Soc Nephrol 2018; 13: 36–44
27. Poyan Mehr A, Tran MT, Ralto KM et al. De novo NAD. Nat Med 2018; 24: 1351–1359
28. El Ters M, Zhou X, Lepping RJ et al. Biological efficacy and safety of niacinamide in patients with ADPKD. Kidney Int Rep 2020; 5: 1271–1279
29. Young DO, Cheng SC, Delmez JA et al. The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Perit Dial Int 2009; 29: 562–567
30. Cozzolino M, Ketteler M, Wagner CA. An expert update on novel therapeutic targets for hyperphosphatemia in chronic kidney disease: preclinical and clinical innovations. Expert Opin Ther Targets 2020; 24: 477–488
31. Zheng M, Cai J, Liu Z et al. Nicotinamide reduces renal interstitial fibrosis by suppressing tubular injury and inflammation. J Cell Mol Med 2019; 23: 3995–4004
32. Zhen X, Zhang S, Xie F et al. Nicotinamide supplementation attenuates renal interstitial fibrosis via boosting the activity of sirtuins. Kidney Dis (Basel) 2021; 7: 186–199
33. Kumakura S, Sato E, Sekimoto A et al. Nicotinamide attenuates the progression of renal failure in a mouse model of adenine-induced chronic kidney disease. Toxins (Basel) 2021; 13: 50
34. Faivre A, Katsyuba E, Verissimo T et al. Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease. Nephrol Dial Transplant 2021; 36: 60–68
35. Jia Y, Kang X, Tan L et al. Nicotinamide mononucleotide attenuates renal interstitial fibrosis after AKI by suppressing tubular DNA damage and senescence. Front Physiol 2021; 12: 649547
36. Gopal E, Fei YJ, Miyauchi S et al. Sodium-coupled and electrogenic transport of B-complex vitamin nicotinic acid by SLC5A8, a member of the Na/glucose co-transporter gene family. Biochem J 2005; 388: 309–316
37. Hershberger KA, Martin AS, Hirschy MD. Role of NAD. Nat Rev Nephrol 2017; 13: 213–225
38. Liu L, Su X, Quinn WJ et al. Quantitative analysis of NAD synthesis-breakdown fluxes. Cell Metab 2018; 27: 1067–1080.e1065
39. Fontecha-Barriuso M, Martin-Sanchez D, Martinez-Moreno JM et al. The role of PGC-1α and mitochondrial biogenesis in kidney diseases. Biomolecules 2020; 10: 347
40. Tran MT, Zsengeller ZK, Berg AH et al. PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection. Nature 2016; 531: 528–532
41. Tran M, Tam D, Bardia A et al. PGC-1α promotes recovery after acute kidney injury during systemic inflammation in mice. J Clin Invest 2011; 121: 4003–4014
42. Fontecha-Barriuso M, Martin-Sánchez D, Martinez-Moreno JM et al. PGC-1α deficiency causes spontaneous kidney inflammation and increases the severity of nephrotoxic AKI. J Pathol 2019; 249: 65–78
43. Ruiz-Andres O, Suarez-Alvarez B, Sánchez-Ramos C et al. The inflammatory cytokine TWEAK decreases PGC-1α expression and mitochondrial function in acute kidney injury. Kidney Int 2015; 89: 399–410
44. Farkh SM. Metabolic stress resistance in acute kidney injury: evidence for a PPAR-gamma-coactivator-1 alpha-nicotinamide adenine dinucleotide pathway. Nephron 2019; 143: 184–187
45. Guan Y, Wang SR, Huang XZ et al. Nicotinamide mononucleotide, an NAD. J Am Soc Nephrol 2017; 28: 2337–2352
46. Giroud-Gerbetant J, Joffraud M, Giner MP et al. A reduced form of nicotinamide riboside defines a new path for NAD. Mol Med 2019; 30: 192–202
47. Piedrafita A, Balayssac S, Mayeur N et al. The tryptophan pathway and nicotinamide supplementation in ischaemic acute kidney injury. Clin Kidney J 2021; sfab050AQ
48. Morevati M, Egstrand S, Nordholm A et al. Effect of NAD+-boosting on kidney ischemia-reperfusion injury. PLoS One 2021; 16: e0252554
49. Zapata-Pérez R, Tammaro A, Schomakers BV et al. Reduced nicotinamide mononucleotide is a new and potent NAD. FASEB J 2021; 35: e21456
50. Agus A, Planchaix J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe 2018; 23: 716–724
51. Lei Y, Sehnert B, Voll RE et al. A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Fas. Kidney Int 2021; 99: 1331–1341